A class action lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud. The complaint claims the company made materially false statements regarding data privacy practices, prescription charging procedures, and failed to disclose regulatory scrutiny and potential penalties. Investors who purchased Hims securities between August 4, 2025 and July 29, 2026 are encouraged to join the case, with a lead plaintiff deadline of November 1, 2026.

Robbins Geller announces a class action lawsuit against Hims & Hers Health, Inc. for allegedly sharing consumers' health information with third-party advertising platforms and charging for prescriptions immediately after intake forms despite claiming personalized consultations. The FTC filed a lawsuit on July 29, 2026, leading to a 15% decline in Hims & Hers stock. Investors with substantial losses can seek lead plaintiff status before November 2, 2026.

Robbins LLP is reminding investors of a pending class action lawsuit against Hims & Hers Health, Inc. for allegedly sharing consumers' sensitive health information with advertising platforms while claiming privacy protection, and engaging in deceptive billing practices. The FTC filed a lawsuit on July 29, 2026, which caused HIMS stock to decline 14.73%. Investors who purchased securities between August 4, 2025 and July 29, 2026 may be eligible to participate, with a lead plaintiff deadline of November 2, 2026.

Hims & Hers Health (HIMS) declined 6.7% on October 14, 2026, significantly underperforming the S&P 500's 1.11% loss. Despite a 6.68% monthly gain, the stock faces upcoming earnings on November 9, 2026, with expectations of $0.07 EPS (up 16.67% YoY) and $893.37M revenue (up 49.15% YoY). The company holds a Zacks Rank #3 (Hold) rating with stagnant consensus estimates.

A class action securities fraud lawsuit has been filed against Hims & Hers Health, Inc. following an FTC lawsuit alleging the telehealth provider shared consumers' sensitive health information with third-party advertising platforms and engaged in deceptive billing practices. The stock declined 14.73% on July 29, 2026, following the FTC announcement. Investors who purchased HIMS securities between August 4, 2025 and July 29, 2026 have until November 2, 2026 to file a lead plaintiff motion.

Hims & Hers Health has launched Hers, its women's health platform, in Australia by rebranding Juniper from its Eucalyptus acquisition. The platform offers personalized care for hair regrowth, menopause, and weight management with 24/7 support. The expansion leverages Eucalyptus' local presence to strengthen brand recognition and recurring revenue in the growing Australian telehealth market, which is projected to grow at 18.2% CAGR through 2034.

Rosen Law Firm has filed securities class action lawsuits against multiple companies. The primary case involves Hims & Hers Health, Inc., alleging the company made false statements about data privacy, charged consumers for prescriptions without proper consultation, and failed to disclose regulatory scrutiny. The firm is seeking lead plaintiffs with a November 2, 2026 deadline. Similar lawsuits have been filed against Papa John's International and Millrose Properties.

Rosen Law Firm announces securities class action lawsuits against Papa John's International (PZZA) and other companies. The Papa John's lawsuit alleges the company made materially false statements about its transformation efforts, concealing that the process was taking longer than expected and failing to prevent market share losses. Investors who purchased stock during the class period may be eligible for compensation. The lead plaintiff deadline is November 2, 2026.

A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making false statements and failing to disclose that it shares consumers' health information with third-party advertising platforms and charges for prescriptions immediately after intake forms are submitted. The FTC, California, and Utah filed a separate lawsuit on July 29, 2026, resulting in a 14.73% stock price decline.

Rosen Law Firm is encouraging investors who purchased Hims & Hers Health, Inc. securities between August 4, 2025 and July 29, 2026 to join a class action lawsuit. The lawsuit alleges that Hims made materially false and misleading statements regarding data privacy practices, prescription charging procedures, and regulatory compliance, which subjected the company to potential fees and penalties.

Hims & Hers Health (NYSE: HIMS) faces a securities class action lawsuit following an FTC complaint alleging the company deceptively shared consumers' health data with third-party advertising platforms like Meta and Snap, and violated billing regulations by charging for prescriptions before medical consultations. The stock plunged 14.7% on July 29, 2026, erasing over $970 million in market value.

Rosen Law Firm has filed securities class action lawsuits against Hims & Hers Health, Duolingo, and Ardelyx. The Hims lawsuit alleges the company made false statements regarding data privacy practices, prescription charging procedures, and failed to disclose regulatory scrutiny and potential penalties. Investors who purchased securities during specified class periods are encouraged to join the litigation before the November 2, 2026 lead plaintiff deadline.